Abzyme Therapeutics
Biotechnology, 321 Jones BLVD, Royersford, Pennsylvania, 19468, United States, 11-50 Employees
Phone Number: 61********
Who is ABZYME THERAPEUTICS
Abzyme Therapeutics is a biopharmaceutical company focused on developing modular single domain VHH antibody fragments for immunotherapy using proprietary antibody generation platforms. Th...
Read More
-
Headquarters: 321 Jones BLVD, Royersford, Pennsylvania, 19468, United States
-
Date Founded: 2010
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8731
Does something look wrong? Fix it. | View contact records from ABZYME THERAPEUTICS
Abzyme Therapeutics Org Chart and Mapping
Email
Phone
Similar Companies to Abzyme Therapeutics
Incyte
-
1001-5000
-
$ 1 Billion and Over
Resilience
-
1001-5000
-
$ 500 Million to 1 Billion
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Abzyme Therapeutics
Answer: Abzyme Therapeutics's headquarters are located at 321 Jones BLVD, Royersford, Pennsylvania, 19468, United States
Answer: Abzyme Therapeutics's phone number is 61********
Answer: Abzyme Therapeutics's official website is https://abzymetx.com
Answer: Abzyme Therapeutics's revenue is $5 Million to $10 Million
Answer: Abzyme Therapeutics's SIC: 8731
Answer: Abzyme Therapeutics has 11-50 employees
Answer: Abzyme Therapeutics is in Biotechnology
Answer: Abzyme Therapeutics top competitors include: Incyte , Resilience
Answer: Abzyme Therapeutics contact info: Phone number: 61******** Website: https://abzymetx.com
Answer: Abzyme Therapeutics is a biopharmaceutical company focused on developing modular single domain VHH antibody fragments for immunotherapy using proprietary antibody generation platforms. The company is located in the Eastern Pennsylvania biotechnology/pharmaceutical hub 30-miles west of Philadelphia. Unique to Abzyme is our proprietary and highly engineered eukaryotic in vitro antibody discovery/optimization platform based on yeast display self-diversifying libraries, rapid target-directed antibody affinity maturation in combination with a FACS single cell sorting approach to identify desired antibodies. Abzymes modular antibody discovery platform incorporates a real-time screening ability to select for key properties such as epitopic diversity, binding affinity, expressibility, solubility, developability, broad-reactivity and target-specificity. Today, the Company has over 60 proprietary and partnered programs in development in therapeutic and diagnostic areas including infectious diseases, immuno-oncology, ophthalmology, inflammation and central nervous system disorders.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month